Back to Details

regulatory-affairs-head

Compare original and translation side by side

🇺🇸

Original

English
🇨🇳

Translation

Chinese

Head of Regulatory Affairs

监管事务负责人

Regulatory strategy development, submission management, and global market access for medical device organizations.
为医疗器械机构提供监管策略制定、申报管理和全球市场准入支持。

Table of Contents

目录

Regulatory Strategy Workflow

监管策略工作流

Develop regulatory strategy aligned with business objectives and product characteristics.
制定与业务目标和产品特性相匹配的监管策略。

Workflow: New Product Regulatory Strategy

工作流：新产品监管策略

  1. Gather product information:
    • Intended use and indications
    • Device classification (risk level)
    • Technology platform
    • Target markets and timeline
  2. Identify applicable regulations per target market:
    • FDA (US): 21 CFR Part 820, 510(k)/PMA/De Novo
    • EU: MDR 2017/745, Notified Body requirements
    • Other markets: Health Canada, PMDA, NMPA, TGA
  3. Determine optimal regulatory pathway:
    • Compare submission types (510(k) vs De Novo vs PMA)
    • Assess predicate device availability
    • Evaluate clinical evidence requirements
  4. Develop regulatory timeline with milestones
  5. Estimate resource requirements and budget
  6. Identify regulatory risks and mitigation strategies
  7. Obtain stakeholder alignment and approval
  8. Validation: Strategy document approved; timeline accepted; resources allocated
  1. 收集产品信息：
    • 预期用途和适应症
    • 设备分类（风险等级）
    • 技术平台
    • 目标市场和时间规划
  2. 识别每个目标市场适用的法规：
    • FDA（美国）：21 CFR Part 820, 510(k)/PMA/De Novo
    • 欧盟：MDR 2017/745, 公告机构（Notified Body）要求
    • 其他市场：加拿大卫生部（Health Canada）、日本PMDA、中国NMPA、澳大利亚TGA
  3. 确定最优监管路径：
    • 对比申报类型（510(k) vs De Novo vs PMA）
    • 评估predicate设备可得性
    • 评估临床证据要求
  4. 制定包含里程碑的监管时间线
  5. 估算资源需求和预算
  6. 识别监管风险及缓解策略
  7. 获得利益相关方对齐和批准
  8. 验证： 策略文档获批、时间线被接受、资源完成分配

Regulatory Pathway Selection Matrix

监管路径选择矩阵

Factor510(k)De NovoPMA
Predicate AvailableYesNoN/A
Risk LevelLow-ModerateLow-ModerateHigh
Clinical DataUsually not requiredMay be requiredRequired
Review Time90 days (MDUFA)150 days180 days
User Fee~$22K (2024)~$135K~$440K
Best ForMe-too devicesNovel low-riskHigh-risk, novel
考量因素510(k)De NovoPMA
有可用predicate设备是否不适用
风险等级低-中低-中高
临床数据通常不需要可能需要必需
审核时长90天（MDUFA）150天180天
申请费用~2.2万美元（2024年）~13.5万美元~44万美元
适用场景仿制类设备新型低风险设备高风险、新型设备

Regulatory Strategy Document Template

监管策略文档模板

REGULATORY STRATEGY

Product: [Name]
Version: [X.X]
Date: [Date]

1. PRODUCT OVERVIEW
   - Intended use: [Statement]
   - Device classification: [Class I/II/III]
   - Technology: [Description]

2. TARGET MARKETS
   | Market | Priority | Timeline |
   |--------|----------|----------|
   | USA    | 1        | Q1 20XX  |
   | EU     | 2        | Q2 20XX  |

3. REGULATORY PATHWAY
   - FDA: [510(k) / De Novo / PMA]
   - EU: [Class] via [Conformity route]
   - Rationale: [Justification]

4. CLINICAL EVIDENCE STRATEGY
   - Requirements: [Summary]
   - Approach: [Literature / Study / Both]

5. TIMELINE AND MILESTONES
   [Gantt or milestone table]

6. RISKS AND MITIGATION
   | Risk | Probability | Impact | Mitigation |
   |------|-------------|--------|------------|

7. RESOURCE REQUIREMENTS
   - Budget: $[Amount]
   - Personnel: [FTEs]
   - External support: [Consultants, CRO]
REGULATORY STRATEGY

Product: [Name]
Version: [X.X]
Date: [Date]

1. PRODUCT OVERVIEW
   - Intended use: [Statement]
   - Device classification: [Class I/II/III]
   - Technology: [Description]

2. TARGET MARKETS
   | Market | Priority | Timeline |
   |--------|----------|----------|
   | USA    | 1        | Q1 20XX  |
   | EU     | 2        | Q2 20XX  |

3. REGULATORY PATHWAY
   - FDA: [510(k) / De Novo / PMA]
   - EU: [Class] via [Conformity route]
   - Rationale: [Justification]

4. CLINICAL EVIDENCE STRATEGY
   - Requirements: [Summary]
   - Approach: [Literature / Study / Both]

5. TIMELINE AND MILESTONES
   [Gantt or milestone table]

6. RISKS AND MITIGATION
   | Risk | Probability | Impact | Mitigation |
   |------|-------------|--------|------------|

7. RESOURCE REQUIREMENTS
   - Budget: $[Amount]
   - Personnel: [FTEs]
   - External support: [Consultants, CRO]

FDA Submission Workflow

FDA申报工作流

Prepare and submit FDA regulatory applications.
准备并提交FDA监管申请。

Workflow: 510(k) Submission

工作流：510(k)申报

  1. Confirm 510(k) pathway suitability:
    • Predicate device identified
    • Substantial equivalence supportable
    • No new intended use or technology concerns
  2. Schedule and conduct Pre-Submission (Q-Sub) meeting if needed
  3. Compile submission package:
    • Cover letter and administrative information
    • Device description and intended use
    • Substantial equivalence comparison
    • Performance testing data
    • Biocompatibility (if patient contact)
    • Software documentation (if applicable)
    • Labeling and IFU
  4. Conduct internal review and quality check
  5. Prepare eCopy per FDA format requirements
  6. Submit via FDA ESG portal with user fee payment
  7. Monitor MDUFA clock and respond to AI/RTA requests
  8. Validation: Submission accepted; MDUFA date received; tracking system updated
  1. 确认510(k)路径适用性：
    • 已确定predicate设备
    • 可证明实质等同性
    • 无新的预期用途或技术风险问题
  2. 按需安排并召开预申报（Q-Sub）会议
  3. 整理申报材料包：
    • 求职信和行政信息
    • 设备说明和预期用途
    • 实质等同性对比材料
    • 性能测试数据
    • 生物相容性数据（若设备接触患者）
    • 软件文档（如适用）
    • 标签和使用说明（IFU）
  4. 开展内部审核和质量检查
  5. 按照FDA格式要求准备电子副本（eCopy）
  6. 通过FDA ESG门户提交并缴纳申请费
  7. 监控MDUFA审核周期，响应AI/RTA要求
  8. 验证： 申报被受理、获得MDUFA审核日期、跟踪系统已更新

Workflow: PMA Submission

工作流：PMA申报

  1. Confirm PMA pathway:
    • Class III device or no predicate
    • Clinical data strategy defined
  2. Complete IDE clinical study if required:
    • IDE approval
    • Clinical protocol execution
    • Study report completion
  3. Conduct Pre-Submission meeting
  4. Compile PMA submission:
    • Administrative and device information
    • Manufacturing information
    • Nonclinical studies
    • Clinical studies
    • Labeling
  5. Submit original PMA application
  6. Address FDA questions and deficiencies
  7. Prepare for FDA facility inspection
  8. Validation: PMA approved; approval letter received; post-approval requirements documented
  1. 确认适用PMA路径：
    • 三类设备或无可用predicate设备
    • 临床数据策略已确定
  2. 按需完成IDE临床研究：
    • IDE获批
    • 临床方案落地执行
    • 研究报告完成
  3. 召开预申报会议
  4. 整理PMA申报材料：
    • 行政和设备信息
    • 生产信息
    • 非临床研究数据
    • 临床研究数据
    • 标签
  5. 提交PMA原始申请
  6. 响应FDA的问题和缺陷整改要求
  7. 为FDA工厂检查做准备
  8. 验证： PMA获批、收到批准函、已记录上市后要求

FDA Submission Timeline

FDA申报时间线

Milestone510(k)De NovoPMA
Pre-Sub MeetingDay -90Day -90Day -120
SubmissionDay 0Day 0Day 0
RTA ReviewDay 15Day 15Day 45
Substantive ReviewDays 15-90Days 15-150Days 45-180
DecisionDay 90Day 150Day 180
里程碑510(k)De NovoPMA
预申报会议第-90天第-90天第-120天
提交申请第0天第0天第0天
RTA审核第15天第15天第45天
实质审核第15-90天第15-150天第45-180天
出具结果第90天第150天第180天

Common FDA Deficiencies

FDA常见申报缺陷

CategoryCommon IssuesPrevention
Substantial EquivalenceWeak predicate comparisonStrong SE argument upfront
Performance TestingIncomplete test protocolsFollow recognized standards
BiocompatibilityMissing endpointsISO 10993 risk assessment
SoftwareInadequate documentationIEC 62304 compliance
LabelingInconsistent claimsEarly labeling review
See: references/fda-submission-guide.md
分类常见问题预防措施
实质等同性predicate设备对比论据不足提前准备充分的实质等同性论证
性能测试测试协议不完整遵循公认标准执行测试
生物相容性缺失测试终点开展ISO 10993风险评估
软件文档不完善符合IEC 62304规范
标签宣称内容不一致提前开展标签审核
参考：references/fda-submission-guide.md

EU MDR Submission Workflow

EU MDR申报工作流

Achieve CE marking under EU MDR 2017/745.
在EU MDR 2017/745法规下获得CE认证。

Workflow: MDR Technical Documentation

工作流：MDR技术文档

  1. Confirm device classification per MDR Annex VIII
  2. Select conformity assessment route based on class:
    • Class I: Self-declaration
    • Class IIa/IIb: Notified Body involvement
    • Class III: Full NB assessment
  3. Select and engage Notified Body (for Class IIa+)
  4. Compile Technical Documentation per Annex II:
    • Device description and specifications
    • Design and manufacturing information
    • General Safety and Performance Requirements (GSPR) checklist
    • Benefit-risk analysis and risk management
    • Clinical evaluation per Annex XIV
    • Post-market surveillance plan
  5. Establish and document QMS per ISO 13485
  6. Submit application to Notified Body
  7. Address NB questions and coordinate audit
  8. Validation: CE certificate issued; Declaration of Conformity signed; EUDAMED registration complete
  1. 按照MDR附录VIII确认设备分类
  2. 根据设备分类选择合格评定路径：
    • I类设备：自我声明
    • IIa/IIb类设备：需公告机构参与
    • III类设备：公告机构全流程评估
  3. 选择并对接公告机构（IIa类及以上设备适用）
  4. 按照附录II要求整理技术文档：
    • 设备说明和规格参数
    • 设计和生产信息
    • 通用安全与性能要求（GSPR）检查表
    • 收益风险分析和风险管理材料
    • 符合附录XIV要求的临床评估
    • 上市后监督计划
  5. 按照ISO 13485建立并记录质量管理体系（QMS）
  6. 向公告机构提交申请
  7. 响应公告机构的问题，配合审核
  8. 验证： 获得CE证书、签署符合性声明、完成EUDAMED注册

MDR Classification Decision Tree

MDR分类决策树

Is the device active?
        │
    Yes─┴─No
     │     │
     ▼     ▼
Is it an   Does it contact
implant?   the body?
  │            │
Yes─┴─No   Yes─┴─No
 │    │     │     │
 ▼    ▼     ▼     ▼
III  IIb  Check   Class I
         contact  (measuring/
         type     sterile if
         and      applicable)
         duration
Is the device active?
        │
    Yes─┴─No
     │     │
     ▼     ▼
Is it an   Does it contact
implant?   the body?
  │            │
Yes─┴─No   Yes─┴─No
 │    │     │     │
 ▼    ▼     ▼     ▼
III  IIb  Check   Class I
         contact  (measuring/
         type     sterile if
         and      applicable)
         duration

Clinical Evidence Requirements by Class

各分类临床证据要求

ClassClinical RequirementDocumentation
IClinical evaluation (CE)CE report
IIaCE with literature focusCE report + PMCF plan
IIbCE with clinical dataCE report + PMCF + clinical study (some)
IIICE with clinical investigationCE report + PMCF + clinical investigation
分类临床要求所需文档
I临床评估（CE）临床评估报告
IIa以文献为核心的临床评估临床评估报告 + PMCF计划
IIb含临床数据的临床评估临床评估报告 + PMCF + 临床研究（部分适用）
III含临床研究的临床评估临床评估报告 + PMCF + 临床研究

Notified Body Selection Criteria

公告机构选择标准

CriterionConsideration
ScopeDevice category expertise
CapacityAvailability and review timeline
ExperienceTrack record in your technology
GeographyProximity for audits
CostFee structure transparency
CommunicationResponsiveness and clarity
See: references/eu-mdr-submission-guide.md
标准考量点
服务范围对应设备品类的专业能力
产能可用资源和审核时间线
经验同类技术的过往服务记录
地理位置审核的便利性
成本费用结构透明度
沟通能力响应速度和沟通清晰度
参考：references/eu-mdr-submission-guide.md

Global Market Access Workflow

全球市场准入工作流

Coordinate regulatory approvals across international markets.
协调全球各市场的监管审批工作。

Workflow: Multi-Market Submission Strategy

工作流：多市场申报策略

  1. Define target markets based on business priorities
  2. Sequence markets for efficient evidence leverage:
    • Phase 1: FDA + EU (reference markets)
    • Phase 2: Recognition markets (Canada, Australia)
    • Phase 3: Major markets (Japan, China)
    • Phase 4: Emerging markets
  3. Identify local requirements per market:
    • Clinical data acceptability
    • Local agent/representative needs
    • Language and labeling requirements
  4. Develop master technical file with localization plan
  5. Establish in-country regulatory support
  6. Execute parallel or sequential submissions
  7. Track approvals and coordinate launches
  8. Validation: All target market approvals obtained; registration database updated
  1. 根据业务优先级确定目标市场
  2. 规划市场申报顺序，最大化复用证据材料：
    • 第一阶段：FDA + 欧盟（参考市场）
    • 第二阶段：互认市场（加拿大、澳大利亚）
    • 第三阶段：主要市场（日本、中国）
    • 第四阶段：新兴市场
  3. 识别各市场的本地化要求：
    • 临床数据认可度
    • 本地代理人/代表要求
    • 语言和标签要求
  4. 搭建主技术文件，制定本地化适配计划
  5. 搭建本地监管支持团队
  6. 并行或按顺序提交申报
  7. 跟踪审批进度，协调上市安排
  8. 验证： 获得所有目标市场审批、注册数据库已更新

Market Priority Matrix

市场优先级矩阵

MarketSizeComplexityRecognitionPriority
USALargeHighN/A1
EULargeHighN/A1-2
CanadaMediumMediumMDSAP2
AustraliaMediumLowEU accepted2
JapanLargeHighLocal clinical3
ChinaLargeVery HighLocal testing3
BrazilMediumHighGMP inspection3-4
市场规模复杂度互认规则优先级
美国大高不适用1
欧盟大高不适用1-2
加拿大中中MDSAP互认2
澳大利亚中低认可欧盟审批2
日本大高需本地临床数据3
中国大极高需本地测试3
巴西中高需GMP审核3-4

Documentation Efficiency Strategy

文档效率优化策略

Document TypeSingle SourceLocalization Required
Technical file coreYesFormat adaptation
Risk managementYesNone
Clinical dataYesBridging assessment
QMS certificateYes (ISO 13485)Market-specific audit
LabelingMaster labelTranslation, local requirements
IFUMaster contentTranslation, local symbols
See: references/global-regulatory-pathways.md
文档类型可通用本地化要求
核心技术文件是格式适配
风险管理文档是无
临床数据是桥接评估
QMS证书是（ISO 13485）按市场要求专项审核
标签主标签通用翻译、适配本地要求
使用说明核心内容通用翻译、适配本地符号规范
参考：references/global-regulatory-pathways.md

Regulatory Intelligence Workflow

监管情报工作流

Monitor and respond to regulatory changes affecting product portfolio.
监控并响应影响产品组合的监管政策变化。

Workflow: Regulatory Change Management

工作流：监管变更管理

  1. Monitor regulatory sources:
    • FDA Federal Register, guidance documents
    • EU Official Journal, MDCG guidance
    • Notified Body communications
    • Industry associations (AdvaMed, MedTech Europe)
  2. Assess relevance to product portfolio
  3. Evaluate impact:
    • Timeline to compliance
    • Resource requirements
    • Product changes needed
  4. Develop compliance action plan
  5. Communicate to affected stakeholders
  6. Implement required changes
  7. Document compliance status
  8. Validation: Compliance action plan approved; changes implemented on schedule
  1. 监控监管信息来源：
    • FDA联邦公报、指南文档
    • 欧盟官方公报、MDCG指南
    • 公告机构通知
    • 行业协会（AdvaMed、MedTech Europe）信息
  2. 评估变更对产品组合的相关性
  3. 评估影响：
    • 合规截止时间
    • 资源需求
    • 所需产品变更
  4. 制定合规行动计划
  5. 同步给相关利益相关方
  6. 落地所需变更
  7. 记录合规状态
  8. 验证： 合规行动计划获批、变更按时落地

Regulatory Monitoring Sources

监管监控信息源

SourceTypeFrequency
FDA Federal RegisterRegulations, guidanceDaily
FDA Device Database510(k), PMA, recallsWeekly
EU Official JournalMDR/IVDR updatesWeekly
MDCG GuidanceEU implementationAs published
ISO/IECStandards updatesQuarterly
Notified BodyAudit findings, trendsPer interaction
信息源类型更新频率
FDA联邦公报法规、指南每日
FDA设备数据库510(k)、PMA、召回信息每周
欧盟官方公报MDR/IVDR更新每周
MDCG指南欧盟法规落地指导发布即更新
ISO/IEC标准更新每季度
公告机构审核发现、趋势每次互动同步

Impact Assessment Template

影响评估模板

REGULATORY CHANGE IMPACT ASSESSMENT

Change: [Description]
Source: [Regulation/Guidance]
Effective Date: [Date]
Assessment Date: [Date]
Assessed By: [Name]

AFFECTED PRODUCTS
| Product | Impact | Action Required | Timeline |
|---------|--------|-----------------|----------|
| [Name]  | [H/M/L]| [Description]   | [Date]   |

COMPLIANCE ACTIONS
1. [Action 1] - Owner: [Name] - Due: [Date]
2. [Action 2] - Owner: [Name] - Due: [Date]

RESOURCE REQUIREMENTS
- Budget: $[Amount]
- Personnel: [Hours/FTEs]

APPROVAL
Regulatory: _________________ Date: _______
Management: _________________ Date: _______
REGULATORY CHANGE IMPACT ASSESSMENT

Change: [Description]
Source: [Regulation/Guidance]
Effective Date: [Date]
Assessment Date: [Date]
Assessed By: [Name]

AFFECTED PRODUCTS
| Product | Impact | Action Required | Timeline |
|---------|--------|-----------------|----------|
| [Name]  | [H/M/L]| [Description]   | [Date]   |

COMPLIANCE ACTIONS
1. [Action 1] - Owner: [Name] - Due: [Date]
2. [Action 2] - Owner: [Name] - Due: [Date]

RESOURCE REQUIREMENTS
- Budget: $[Amount]
- Personnel: [Hours/FTEs]

APPROVAL
Regulatory: _________________ Date: _______
Management: _________________ Date: _______

Decision Frameworks

决策框架

Pathway Selection Decision Tree

路径选择决策树

Is predicate device available?
            │
        Yes─┴─No
         │     │
         ▼     ▼
    Is device   Is risk level
    substantially  Low-Moderate?
    equivalent?       │
         │        Yes─┴─No
     Yes─┴─No      │     │
      │     │      ▼     ▼
      ▼     ▼   De Novo  PMA
    510(k)  Consider      required
           De Novo
           or PMA
Is predicate device available?
            │
        Yes─┴─No
         │     │
         ▼     ▼
    Is device   Is risk level
    substantially  Low-Moderate?
    equivalent?       │
         │        Yes─┴─No
     Yes─┴─No      │     │
      │     │      ▼     ▼
      ▼     ▼   De Novo  PMA
    510(k)  Consider      required
           De Novo
           or PMA

Pre-Submission Meeting Decision

预申报会议决策规则

FactorSchedule Pre-SubSkip Pre-Sub
Novel Technology✓
New Intended Use✓
Complex Testing✓
Uncertain Predicate✓
Clinical Data Needed✓
Well-established✓
Clear Predicate✓
Standard Testing✓
考量因素安排预申报跳过预申报
新型技术✓
新的预期用途✓
测试流程复杂✓
predicate设备不明确✓
需要临床数据✓
技术成熟✓
predicate设备明确✓
测试符合标准流程✓

Regulatory Escalation Criteria

监管升级标准

SituationEscalation LevelAction
Submission rejectionVP RegulatoryRoot cause analysis, strategy revision
Major deficiencyDirectorCross-functional response team
Timeline at riskManagementResource reallocation review
Regulatory changeVP RegulatoryPortfolio impact assessment
Safety signalExecutiveImmediate containment and reporting
场景升级级别行动
申报被拒监管副总裁根因分析、调整策略
重大缺陷总监成立跨职能响应团队
时间线存在风险管理层评估资源重新分配
监管政策变更监管副总裁评估产品组合整体影响
安全信号高管层立即采取遏制措施并上报

Tools and References

工具与参考资料

Scripts

脚本

ToolPurposeUsage
regulatory_tracker.pyTrack submission status and timelines
python regulatory_tracker.py
Regulatory Tracker Features:
  • Track multiple submissions across markets
  • Monitor status and target dates
  • Identify overdue submissions
  • Generate status reports
工具用途使用方式
regulatory_tracker.py跟踪申报状态和时间线
python regulatory_tracker.py
监管跟踪工具功能：
  • 跟踪多市场多项目申报进度
  • 监控状态和目标日期
  • 识别逾期申报
  • 生成状态报告

References

参考资料

DocumentContent
fda-submission-guide.mdFDA pathways, requirements, review process
eu-mdr-submission-guide.mdMDR classification, technical documentation, clinical evidence
global-regulatory-pathways.mdCanada, Japan, China, Australia, Brazil requirements
iso-regulatory-requirements.mdISO 13485, 14971, 10993, IEC 62304, 62366 requirements
文档内容
fda-submission-guide.mdFDA路径、要求、审核流程
eu-mdr-submission-guide.mdMDR分类、技术文档、临床证据要求
global-regulatory-pathways.md加拿大、日本、中国、澳大利亚、巴西监管要求
iso-regulatory-requirements.mdISO 13485、14971、10993、IEC 62304、62366要求

Key Performance Indicators

关键绩效指标

KPITargetCalculation
First-time approval rate>85%(Approved without major deficiency / Total submitted) × 100
On-time submission>90%(Submitted by target date / Total submissions) × 100
Review cycle compliance>95%(Responses within deadline / Total requests) × 100
Regulatory hold time<20%(Days on hold / Total review days) × 100
KPI目标值计算方式
首次通过率>85%(无重大缺陷获批数量 / 总申报数量) × 100
申报及时率>90%(按目标日期提交数量 / 总申报数量) × 100
审核响应合规率>95%(截止日期前响应数量 / 总反馈请求数量) × 100
监管搁置占比<20%(搁置天数 / 总审核天数) × 100

Related Skills

相关技能

SkillIntegration Point
mdr-745-specialistDetailed EU MDR technical requirements
fda-consultant-specialistFDA submission deep expertise
quality-manager-qms-iso13485QMS for regulatory compliance
risk-management-specialistISO 14971 risk management
技能集成点
mdr-745-specialistEU MDR技术要求细节
fda-consultant-specialistFDA申报深度专业知识
quality-manager-qms-iso13485监管合规对应的QMS体系
risk-management-specialistISO 14971风险管理